Cytokine Release Syndrome
Conditions
Interventions
Treated group:NA
Control group:NA
Sponsors
Southern Medical University Southern Hospital
Eligibility
Sex/Gender
All
Age
1 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily signed informed consent for tocilizumab treatment; 2. Age <= 18; 3. Patients who were admitted to the Department of Pediatrics, Nanfang Hospital, Southern Medical University, from July 2018 to June 2023, and have been missing for more than one year; 4. Patients who have undergone first-time allogeneic hematopoietic stem cell transplantation with a myeloablative conditioning regimen and who develop cytokine release syndrome within 1 week after stem cell infusion;
Exclusion criteria
Exclusion criteria: 1. Post-fludarabine and cyclophosphamide conditioning regimen; 2. The main diagnoses are immunodeficiency diseases, solid tumors, hemophilic syndrome, chronic activated Epstein-Barr virus infection, etc; 3. Autologous stem cell transplantation, secondary or tertiary allogeneic hematopoietic stem cell transplantation; 4. The electronic medical record system has no records or important data is missing;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Temperature; | — |
Countries
China
Contacts
Public ContactXiaoqin Feng
Southern Medical University Southern Hospital
Outcome results
None listed